Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.16M, -15.1% YoY · Filed Aug 13, 2026
Ensysce Biosciences, Inc. (ENSC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.2 million and a net loss of $2.6 million.
Revenue
$1.16M
-15.1% vs year-ago quarter
Net income
$-2.57M
-48.3% vs year-ago quarter
Operating cash flow
$-1.96M
+27.5% vs year-ago quarter
Free cash flow
$-1.53M
+23.3% vs prior quarter
EPS
$-0.20
+74.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
19.46M
+555.5% vs year-ago quarter
Net cash
—
Operating margin
-281.3%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENSC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1716947
- Former names
- Leisure Acquisition Corp. (until Jun 30, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $960,999 | $1.9M | $493,104 | $1.4M |
| Operating income | -$2.6M | -$3.6M | -$2.8M | -$3.7M | -$1.8M |
| Net income | -$2.6M | -$3.6M | -$2.8M | -$3.7M | -$1.7M |
| Diluted EPS | -$0.20 | -$0.52 | -$0.75 | -$1.29 | -$0.79 |
| Operating cash flow | -$2.0M | -$3.5M | -$1.5M | -$1.9M | -$2.7M |
| Free cash flow | — | — | -$1.5M | -$2.0M | — |
| Total assets | $3.0M | $2.2M | $7.5M | $3.2M | $5.6M |
| Total liabilities | $4.1M | $2.8M | $4.6M | $2.3M | $2.5M |
| Stockholders' equity | -$781,697 | -$340,042 | $3.2M | $1.2M | $3.4M |
| Cash and investments | $676,704 | $745,482 | $4.3M | $1.7M | $2.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 4, 2026 | Oct 29, 2026 |
| 8-K/A | Amended current report | Oct 16, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 29, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Other events
|
Aug 25, 2026 | Aug 25, 2026 |
| 8-K |
Current report
Other events
|
Aug 24, 2026 | Aug 24, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 547 Ensysce Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.